Pregnancy as an opportunity to improve lifelong health, SMARThealth Pregnancy
Background
Pregnancy complications such as high blood pressure (also known as hypertension), gestational diabetes and anaemia increase risks to the mother and baby during pregnancy the world over, but the burden is particularly great in certain contexts, including many parts of rural India.
These complications can have longer-term consequences after birth. For instance, up to 50% of women who experience gestational diabetes will go on to develop type 2 diabetes within 5-10 years. Meanwhile, following preeclampsia (a disorder of pregnancy that is marked by the onset of high blood pressure), women are at increased risk of cardiovascular complications, while anaemia (which over half of the women in India experience during their pregnancy) can markedly affect a woman’s well-being, energy and productivity in society if it persists.
These challenges are coupled with the reality that non-communicable diseases (NCDs) such as cardiovascular diseases and diabetes are two of the l
Clinical and community trials
About this study
Individuals receiving dialysis are at risk of heart failure and heart-related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis.
Spironolactone is a medication used to prevent heart failure and related deaths in patients that do not require dialysis. It works by blocking a hormone (aldosterone) in your body that causes high blood pressure and can damage the heart. Although spironolactone is very effective in patients that do not require dialysis, we do not know if spironolactone is effective in dialysis patients. Our research will help determine if spironolactone reduces heart failure and heart related deaths in dialysis patients.
Eligibility criteria
Inclusion
Age
≥45 years or
≥18 with a history of diabetes
On dialysis ≥ 90 days
On either
Haemodialysis prescribed at least 2 treatments per week or
Peritoneal dialysis prescribed with at least 1 exc
ASHVINS: Managing Depression in Cancer Patients in India
BackgroundDepression has a prevalence of around 30% in patients with cancer. Research shows that managing comorbid depression can be beneficial for overall care of cancer. But in India, there is no systematic identification or treatment of comorbid depression in such cases. Even in tertiary care centres, depression is managed only if patients express florid symptoms, and routine screening is not done. The effect of not treating depression both on the health of the individual and the economic impact on the health system can be quite significant as it reduces treatment adherence, increases emergency visits and hospital admissions, and prolongs illness.Monitoring mood fluctuations and linking them with stressors, both those related to cancer or those related to psychosocial issues, are key components of integrated cancer care. Strategies to increase awareness about one’s mental health status through self-monitoring and facilitate contact with mental health professionals using an algorithm-based referral system
Financial penalties for decreasing incidence, death and disability due to road traffic injuries: policy brief
Policy & Practice Report
Rapid Policy Brief: Mid-level health providers (MLHPs) for primary healthcare
Policy & Practice Report
George Institute submission on the Role and Functions of an Australian CDC
Policy & Practice Report
Community Action for Health: Evidence from India
Policy & Practice Report
Lessons to be learned in relation to the Australian bushfire season 2019-20
Policy & Practice Report
Senate Select Committee on COVID-19 – The Australian Government’s Response
Policy & Practice Report
Response to the Review of the Food Standards Australia New Zealand Act 1991 Draft Regulatory Impact Statement
Policy & Practice Report
Endometriosis: Charting the way forward in Policy and Practice
Policy & Practice Report
The power of a wellbeing economy for climate, health and equity
Policy & Practice Report